Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

EADV 2020 | Efficacy and Safety of Mirikizumab Versus Secukinumab and Placebo in the Treatment of Moderate-to-sever Psoriasis: 52-week results from OASIS-2, a Multicenter, Randomized, Double-blind Study

Biologics 2020

Presented by Kim A. Papp, MD, PhD

A report from the 29th Congress of the European Academy of Dermatology and Venereology 

Intro and design: Mirikizumab is a humanized monoclonal antibody that binds the IL-23-p19 subunit. This study assessed PASI-90 and sPGA(0,1) responses of mirikizumab (MIR) q4weeks (induction) then q8weeks (maintenance), versus placebo and secukinumab (SEC) standard dosing

 MIR 250mg 

 SEC 300mg 

 Placebo 

 MIR 125mg 

 PASI-90 / PASI-100 response 

 Week 16 

 74.4% / 37.7% 

 72.8% / 36.6% 

 6.3% 

 Week 52 

 82.4% / 58.8% 

 69.4% / 42.9% 

 81.4% / 53.9% 

 sPGA response 

 Week 16 

 79.5% 

 76.3% 

 6.3% 

 Week 52 

 83.3% 

 68.5% 

 83.1% 

 

Adverse events: Similar across treatment arms, most mild-moderate. More major adverse cardiovascular events and 1 death (myocardial infarction) occurred in mirikizumab arms.

Conclusion: Mirikizumab demonstrated superiority to both placebo and secukinumab at week 16 and 52, with durable response.


Search:

Filter by Topic:


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK